TipRanks
Novavax: More Catalysts on the Horizon
The Covid-19 landscape is constantly evolving, but recent times have seen mixed blessings for coronavirus stocks. Pfizer has shown it is increasingly dominant in the Covid-19 vaccine space while the stock got an additional boost from the prospect of bringing to market a Covid-19 pill which could significantly reduce high-risk patients’ hospitalizations and deaths. At the opposite end of the scale, both developments have been bad news for Moderna, whose Covid-19 vaccine is losing market share to
